229 related articles for article (PubMed ID: 2159104)
21. Response and decline of serum IgG antibodies to pertussis toxin, filamentous hemagglutinin and pertactin in children with pertussis.
Isacson J; Trollfors B; Hedvall G; Taranger J; Zackrisson G
Scand J Infect Dis; 1995; 27(3):273-7. PubMed ID: 8539553
[TBL] [Abstract][Full Text] [Related]
22. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers.
Sato Y; Sato H
Tokai J Exp Clin Med; 1988; 13 Suppl():79-88. PubMed ID: 2908530
[TBL] [Abstract][Full Text] [Related]
23. Genital antibody responses in mice after intranasal infection with an attenuated candidate vector strain of Bordetella pertussis.
Mielcarek N; Nordström I; Menozzi FD; Locht C; Holmgren J
Infect Immun; 2000 Feb; 68(2):485-91. PubMed ID: 10639408
[TBL] [Abstract][Full Text] [Related]
24. Mouse-protecting and histamine-sensitizing activities of pertussigen and fimbrial hemagglutinin from Bordetella pertussis.
Munoz JJ; Arai H; Cole RL
Infect Immun; 1981 Apr; 32(1):243-50. PubMed ID: 6260681
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of serologic assays for diagnosis of whooping cough.
Granström G; Wretlind B; Salenstedt CR; Granström M
J Clin Microbiol; 1988 Sep; 26(9):1818-23. PubMed ID: 2903178
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.
Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF
Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625
[TBL] [Abstract][Full Text] [Related]
27. Protection of mice against respiratory Bordetella pertussis infection by intranasal immunization with P.69 and FHA.
Roberts M; Cropley I; Chatfield S; Dougan G
Vaccine; 1993; 11(8):866-72. PubMed ID: 8356847
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of pertussis vaccines consisted of antigens detoxified with tea-leaf catechins.
Watanabe M; Funaishi K; Takeo T; Endoh M
Vaccine; 2000 Dec; 19(9-10):1204-10. PubMed ID: 11137258
[TBL] [Abstract][Full Text] [Related]
29. Optimization of immunization schedule to standardize antibody response in mice to pertussis vaccines.
Tiru M; Jäätmaa E; Gillenius P; Askelöf P
Dev Biol Stand; 1985; 61():469-75. PubMed ID: 2872128
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity of a three-component acellular pertussis vaccine administered at birth.
Belloni C; De Silvestri A; Tinelli C; Avanzini MA; Marconi M; Strano F; Rondini G; Chirico G
Pediatrics; 2003 May; 111(5 Pt 1):1042-5. PubMed ID: 12728086
[TBL] [Abstract][Full Text] [Related]
31. [Serum immunoglobulin IgG subclass distribution of antibody responses to pertussis toxin and filamentous hemagglutinin of Bordetella pertussis in patients with whooping cough].
Rastawicki W; Smietańska K; Rokosz-Chudziak N; Jagielski M
Med Dosw Mikrobiol; 2013; 65(4):269-74. PubMed ID: 24730215
[TBL] [Abstract][Full Text] [Related]
32. Fusion expression and immunogenicity of Bordetella pertussis PTS1-FHA protein: implications for the vaccine development.
Jinyong Z; Xiaoli Z; Weijun Z; Ying G; Gang G; Xuhu M; Quanming Z
Mol Biol Rep; 2011 Mar; 38(3):1957-63. PubMed ID: 20878241
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of serology and nasopharyngeal cultures for diagnosis of pertussis in a vaccine efficacy trial.
Hallander HO; Storsaeter J; Möllby R
J Infect Dis; 1991 May; 163(5):1046-54. PubMed ID: 2019753
[TBL] [Abstract][Full Text] [Related]
34. Genetic studies of the molecular basis of whooping cough.
Weiss AA; Hewlett EL; Myers GA; Falkow S
Dev Biol Stand; 1985; 61():11-9. PubMed ID: 2872097
[TBL] [Abstract][Full Text] [Related]
35. Antibody responses after vaccination and disease against leukocytosis promoting factor, filamentous hemagglutinin, lipopolysaccharide and a protein binding to complement-fixing antibodies induced during whooping cough.
Winsnes R; Lønnes T; Møgster B; Berdal BP
Dev Biol Stand; 1985; 61():353-65. PubMed ID: 2872124
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children.
Podda A; Carapella De Luca E; Titone L; Casadei AM; Cascio A; Bartalini M; Volpini G; Peppoloni S; Marsili I; Nencioni L
J Pediatr; 1993 Jul; 123(1):81-4. PubMed ID: 8320630
[TBL] [Abstract][Full Text] [Related]
37. Serum anti-PT and anti-FHA antibody levels, and agglutinin titers after administration of acellular pertussis vaccines.
Kuno-Sakai H; Kimura M; Sato Y; Tsunoda A; Urano T; Isomura S; Kamiya H
Acta Paediatr Jpn; 1989 Apr; 31(2):120-6. PubMed ID: 2516691
[TBL] [Abstract][Full Text] [Related]
38. Immune responses to Bordetella pertussis infection and vaccination.
Tomoda T; Ogura H; Kurashige T
J Infect Dis; 1991 Mar; 163(3):559-63. PubMed ID: 1995729
[TBL] [Abstract][Full Text] [Related]
39. Purification and immunogenicity of a recombinant Bordetella pertussis S1S3FHA fusion protein expressed by Streptococcus gordonii.
Lee SF; Halperin SA; Knight JB; Tait A
Appl Environ Microbiol; 2002 Sep; 68(9):4253-8. PubMed ID: 12200273
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of pertussis components in an acellular vaccine, as assessed in a murine model of respiratory infection and a murine intracerebral challenge model.
Watanabe M; Komatsu E; Abe K; Iyama S; Sato T; Nagai M
Vaccine; 2002 Jan; 20(9-10):1429-34. PubMed ID: 11818163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
